The estimated Net Worth of G Leonard Jr Baker is at least $120 Milion dollars as of 11 June 2021. Mr. Baker owns over 150,000 units of Corcept Therapeutics Inc stock worth over $117,610,172 and over the last 21 years he sold CORT stock worth over $1,838,983. In addition, he makes $234,980 as Independent Director at Corcept Therapeutics Inc.
George has made over 32 trades of the Corcept Therapeutics Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he bought 150,000 units of CORT stock worth $3,229,500 on 11 June 2021.
The largest trade he's ever made was buying 1,216,196 units of Corcept Therapeutics Inc stock on 6 February 2009 worth over $839,175. On average, George trades about 113,300 units every 90 days since 2004. As of 11 June 2021 he still owns at least 3,308,303 units of Corcept Therapeutics Inc stock.
You can see the complete history of Mr. Baker stock trades at the bottom of the page.
George Leonard Baker Jr. serves as Independent Director of the Company. Since 1973, Mr. Baker has been a Managing Director of the General Partner of Sutter Hill Ventures, a venture capital firm in Palo Alto, California. Mr. Baker currently serves on the board of directors of private companies and non-profits. He received his B.A. from Yale University and his M.B.A. from Stanford University. Mr. Baker brings to our Board expertise in finance, strategic transactions and business operations.
As the Independent Director of Corcept Therapeutics Inc, the total compensation of George Baker at Corcept Therapeutics Inc is $234,980. There are 13 executives at Corcept Therapeutics Inc getting paid more, with Joseph Belanoff having the highest compensation of $4,958,970.
George Baker is 77, he's been the Independent Director of Corcept Therapeutics Inc since 1999. There are no older and 18 younger executives at Corcept Therapeutics Inc.
G's mailing address filed with the SEC is 755 PAGE MILL ROAD, SUITE A-200, , PALO ALTO, CA, 94304-1005.
Over the last 21 years, insiders at Corcept Therapeutics Inc have traded over $107,318,493 worth of Corcept Therapeutics Inc stock and bought 71,912,273 units worth $127,133,071 . The most active insiders traders include Patrick G Enright, Allen Andersson oraz Ventures, Llc Paperboy. On average, Corcept Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $8,010,233. The most recent stock trade was executed by William Guyer on 3 September 2024, trading 10,000 units of CORT stock currently worth $216,500.
leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
Corcept Therapeutics Inc executives and other stock owners filed with the SEC include: